Clinical Trials Logo
  1. Home
  2. Bone Loss
  3. NCT05303636

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Bone Loss Clinical Trial

Official title:
A Multicenter, Open-label, Controlled Study to Investigate the Effect of Either LF111 or Drospirenone Chewable Tablets on Bone Mineral Density in Adolescent and Adult Women in Comparison With Non-users of Hormonal Contraceptive Methods

Clinical Trial Summary

The primary objective of this study is to evaluate the impact of LF111 and drospirenone (DRSP) 3.5 mg chewable tablets on bone mineral density (BMD) at the lumbar spine after 12 months (13 medication cycles) of investigation in comparison to non-hormonal contraceptive methods. Secondary objectives include further evaluating the impact of LF111 and DRSP 3.5 mg chewable tablets on BMD and bone turnover after 12 months (13 medication cycles) in comparison to non-hormonal contraceptive methods and assessing the general safety and tolerability of LF111 and DRSP 3.5 mg chewable tablets in comparison to non-hormonal contraceptive methods. Exploratory objectives include evaluating the impact of LF111 and DRSP 3.5 mg chewable tablets on body fat and lean mass after 12 months (13 medication cycles) of investigation.

Clinical Trial Description

This is a Phase IV, prospective, multicenter, open-label, controlled, non-randomized trial in female subjects between 14 to 45 years of age who are postmenarcheal for at least two years and premenopausal. Subjects who choose to take the trial medication (LF111 tablet or drospirenone [DRSP] 3.5 mg chewable tablet [USA only]) will be compared to subjects who choose to use non-hormonal contraceptive methods, enrolled in a 1:1 ratio. Subjects will also be separated into two cohorts: cohort 1 as adolescents aged 14-17, and cohort 2 as adults aged 18-45. At Visit 1 (screening), informed consent/assent will be obtained, and the screening procedures will be performed. At Visit 2 (allocation to treatment), after confirming the subject's eligibility, subjects who choose to use LF111 or DRSP 3.5 mg chewable tablets (USA only) for pregnancy prevention will be provided with LF111 or DRSP 3.5 mg chewable tablets. The subjects will attend additional on-site visits 6 months and 12 months after Visit 2 (end of investigational phase) or within one week after premature trial discontinuation for routine safety assessments. The primary objective of this study is to evaluate the impact of LF111 and DRSP 3.5 mg chewable tablets on bone mineral density (BMD) at the lumbar spine after 12 months (13 medication cycles) of investigation in comparison to non-hormonal contraceptive methods. Secondary objectives include further evaluating the impact of LF111 and DRSP 3.5 mg chewable tablets on BMD and bone turnover after 12 months (13 medication cycles) in comparison to non-hormonal contraceptive methods and assessing the general safety and tolerability of LF111 and DRSP 3.5 mg chewable tablets in comparison to non-hormonal contraceptive methods. Exploratory objectives include evaluating the impact of LF111 and DRSP 3.5 mg chewable tablets on body fat and lean mass after 12 months (13 medication cycles) of investigation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05303636
Study type Interventional
Source Insud Pharma
Contact Study Director
Phone +34 - 91 771 15 00
Email comunicacion@insudpharma.com
Status Recruiting
Phase Phase 4
Start date March 28, 2022
Completion date March 2027
View Details
See also
  Status Clinical Trial Phase
Completed NCT04043286 - The Effects of Dis/Reconnection of Implant Abutments on Peri-implant Bone Levels N/A
Recruiting NCT03046147 - The Effect of Roux-en-Y Gastric Bypass on Bone Turnover N/A
Completed NCT01292395 - Effects of Dietary Protein on Musculoskeletal Health During Calorie Deficiency N/A
Completed NCT00485953 - Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy Phase 4
Completed NCT00674453 - The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation Phase 2
Completed NCT00181584 - Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer Phase 2
Withdrawn NCT04380155 - Cycling Duration and Bone Markers in in Active Young Adults N/A
Active, not recruiting NCT04779216 - Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa Phase 3
Completed NCT05371418 - Comparative Clinical and Radiographical Evaluation of Treatment of Angular Bone Defect Related to Over Erupted Tooth Using GTR Followed by Orthodontic Intrusion Versus Orthodontic Intrusion Followed by GTR N/A
Not yet recruiting NCT04345250 - Bone Response to Exercise and Energy Restriction in Young Adults N/A
Active, not recruiting NCT05301400 - Marginal Bone Loss in Single Implant Restaurations With Different Methods N/A
Active, not recruiting NCT05405894 - Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
Recruiting NCT04983758 - 20-year Implant Survival in Periodontally Healthy and Compromised Patients
Recruiting NCT04713774 - Bone Density and Vascular Calcifications Evolution After Renal Transplant
Completed NCT04279392 - Healthy Body, Healthy Bones After Bariatric Surgery Trial Phase 1/Phase 2
Completed NCT04332679 - Non-resorbable Membranes Versus Titanium Meshes and Resorbable Membranes N/A
Completed NCT05721014 - Effects of OsteoStrong vs. Individually Adapted and Combined Training on Bone Health N/A
Recruiting NCT04883502 - Study of the Role of the Induced Membrane in the Reconstruction of Bone Loss in the Limbs
Not yet recruiting NCT05066815 - Evaluation of Crestal Bone Loss Around Short Dental Implants As Affected By Two Suprastructure Materials N/A
Completed NCT03292146 - Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study Phase 3